longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Catheter Precision

VTAK

0.17506.06% ( +0.0100 )
Closed: Sep 11, 16:00:00 (EDT)
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Q2 FY2026 EarningsFY26 Q2 results missed consensus expectations significantly on the top line, with revenue of $1.02M vs. $2.02M expected. Gross margin plummeted to 9.62% compared to the 73.00% consensus, primarily due to the high-cost structure of the newly acquired private aviation segment. While GAAP Net Loss of $3.31M was wider than the $2.00M expected loss, GAAP EPS of -$0.92 beat the -$1.90 consensus due to significant share dilution from convertible preferred stock issuances. Management continues to face substantial doubt regarding the company's ability to continue as a going concern.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Catheter Precision(VTAK) the Revenue is 1.019 M (+380.7%);the EBIT is -3.955 M (-39.36%);the EPS is -0.923 (+87.32%).

Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B380.66%
----
----
EBIT
-0.00B39.36%
----
----
EPS
-0.923287.32%
----
----

Revenue

ActualEstimateUnit: USD
qf

EBIT

ActualEstimateUnit: USD
qf

Net income

ActualEstimateUnit: USD
qf

EPS

ActualEstimateUnit: USD
qf